- Home
- SMG vs NAMS Comparison
SMG vs NAMS Comparison
Compare SMG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMG | NAMS |
|---|---|---|
| Founded | 1868 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | SMG | NAMS |
|---|---|---|
| Price | $61.60 | $28.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $73.00 | $46.75 |
| AVG Volume (30 Days) | ★ 911.7K | 838.8K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | ★ 504.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,016,500,000.00 | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $2.63 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $52.00 | $16.79 |
| 52 Week High | $72.35 | $42.00 |
Technical Indicators
Market Signals| Indicator | SMG | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 36.61 |
| Support Level | $58.74 | $23.48 |
| Resistance Level | $65.38 | $37.25 |
| Average True Range (ATR) | 2.86 | 1.69 |
| MACD | -0.16 | -0.61 |
| Stochastic Oscillator | 23.67 | 7.88 |
Price Performance
Historical ComparisonAbout SMG Scotts Miracle-Gro Company (The)
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.